BeneVir Biopharm

BeneVir Utilizes Its Proprietary T-Stealth Oncolytic Virus Platform to Design Oncolytic Viruses Capable of Infecting and Destroying Cancer Cells. T-Stealth Oncolytic Viruses Can Evade the Immune System, Thereby Destroying Cancer Cells Directly or Through Immune System Activation. This Technology Platform Reduces the Antagonistic Effect Between Oncolytic Viruses and Immune Checkpoint Inhibitors, Enabling Their Simultaneous Use and Maximizing Synergistic Clinical Relief Effects.